ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

What Is a Biosimilar?

by Jennifer Fink • August 16, 2017

  • Tweet
  • Email
Print-Friendly Version

The question, of course, is how significant are those differences? If the products are different enough, an immune reaction might be provoked. “There’s no question that there is some risk of immunogenicity when molecules aren’t 100% similar,” said Aaron Hakim, a third-year Yale medical student and co-author of a 2017 JAMA article on the adoption of biosimilars for chronic disease (JAMA. 2017;317:2163-2164). “If your immune system was fine with product A but product B is slightly different, it may cause adverse effects. The drug may no longer be effective for you.”

You Might Also Like

  • Sinus Surgery Is Still an Essential Part of Patient Care
  • What Is a Biosimilar?
  • Why Otolaryngologists Should Embrace Off-Label Drugs, Devices
  • How the U.S. FDA Approves Medical Devices
Explore This Issue
August 2017

It’s important to note that immunogenicity is a risk even with biologics, because batch-to-batch variability exists in the production of therapeutic antibodies even when biologics are produced in the same plant, by the same manufacturer, and using the same process.

An International Perspective

Europe is far ahead of the United States in adopting biologics and biosimilars. In fact, the European Medicines Agency (EMA) approved 109 biologics between 2011 and 2016, compared with the 85 approved by the FDA in that same time frame (J Allergy Clin Immunol. 2017;139:1461-1464). Thirty biosimilars have already been approved in Europe, compared with just four here in the U.S.

What accounts for the difference?

“The regulatory paradigm for the approval of biosimilars in the United States really only started with the Affordable Care Act,” Hakim said. The Biologics Price Competition and Innovation Act passed in 2010 as part of the Affordable Care Act, and it is “only in the last several months that the FDA has put out guidance for what it required to be an interchangeable biosimilar, meaning a biosimilar that can be substituted for the branded biologic, at the level of the pharmacy,” Hakim said. That document was originally expected before the end of 2015; it was January 2017 when the FDA released draft guidance for industry regarding how to demonstrate interchangeability.

In contrast, the Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues went into effect in 2006 in Europe. There, biosimilars must be proven similar to a reference biologic in terms of safety, efficacy, and quality, but drug manufacturers do not need to conduct clinical trials as extensive as those required for approval of the original biologic. (It is expected that FDA approval of biosimilars in the U.S. will require switching studies to demonstrate that patients can alternate between the original biologic and the biosimilar without diminished efficacy or serious side effects.)

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Home Slider Tagged With: biologic drugs, biologics, biosimilar, otolaryngology, pharmaceuticalsIssue: August 2017

You Might Also Like:

  • Sinus Surgery Is Still an Essential Part of Patient Care
  • What Is a Biosimilar?
  • Why Otolaryngologists Should Embrace Off-Label Drugs, Devices
  • How the U.S. FDA Approves Medical Devices

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • A Look at the Latest Research on Subglottic Stenosis
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.